Hutchison China MediTech has announced a change (“2018 Amendment”) to the 2013 License and Collaboration Agreement on fruquintinib with Lilly Shanghai, an affiliate of Eli Lilly and Company.    The 2018 Amendment covers adjustments in the respective roles and responsibilities of Chi-Med and Lilly, in China, for the development and commercialization of fruquintinib in the areas of future life cycle planning and development, collaborations for co-development of fruquintinib with other thir...